ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0103

Common and Rare Variant Contributions to Familial Aggregation in Spondyloarthritis
Abstract Number: 1417

Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis
Abstract Number: 0484

Comparable Efficacy of FK-Tocilizumab and Reference Tocilizumab in Rheumatoid Arthritis Patients With and Without Prior Biologic Exposure
Abstract Number: 2633

Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Abstract Number: 1023

Comparative Analysis of Oral Health and Dental Care in Patients With Immune-Mediated and Non-Immune-Mediated Rheumatic Diseases
Abstract Number: 2294

Comparative Analysis of Patients Included in Trials Utilizing Biologic Drugs in the Treatment of Primary Sjögren’s Syndrome
Abstract Number: 1743

Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis
Abstract Number: 1665

Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort
Abstract Number: 1224

Comparative Effectiveness of Duloxetine versus Pregabalin in Fibromyalgia: A Large-Scale, Real-World Study Across 300,000 Patients
Abstract Number: 2109

Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Abstract Number: 2370

Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
Abstract Number: 1258

Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Abstract Number: 2698

Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study
Abstract Number: 1161

Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases
Abstract Number: 0254

Comparative Outcomes in MAGIC Syndrome versus Relapsing Polychondritis Alone: A Propensity-Matched Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].